Oscotec Inc (039200) - Total Liabilities
Based on the latest financial reports, Oscotec Inc (039200) has total liabilities worth ₩39.81 Billion KRW (≈ $26.98 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oscotec Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Oscotec Inc's total liabilities have evolved over time, based on quarterly financial data. See Oscotec Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Oscotec Inc Competitors by Total Liabilities
The table below lists competitors of Oscotec Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beyondsoft Corp
SHE:002649
|
China | CN¥1.44 Billion |
|
Qingdao Eastsoft Communic Tech
SHE:300183
|
China | CN¥390.07 Million |
|
Qingdao Kutesmart Co Ltd
SHE:300840
|
China | CN¥361.17 Million |
|
China Bills Finance Corp
TW:2820
|
Taiwan | NT$236.43 Billion |
|
Jiangsu Flowers King
SHG:603007
|
China | CN¥1.26 Billion |
|
Dilip Buildcon Limited
NSE:DBL
|
India | Rs144.99 Billion |
|
Changchun Engley Automobile Industry Co.Ltd.
SHG:601279
|
China | CN¥3.01 Billion |
|
Maravai Lifesciences Holdings Inc
NASDAQ:MRVI
|
USA | $417.33 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Oscotec Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 039200 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oscotec Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oscotec Inc (2011–2025)
The table below shows the annual total liabilities of Oscotec Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩43.01 Billion ≈ $29.14 Million |
+11.94% |
| 2024-12-31 | ₩38.42 Billion ≈ $26.04 Million |
+1.47% |
| 2023-12-31 | ₩37.86 Billion ≈ $25.66 Million |
+78.36% |
| 2022-12-31 | ₩21.23 Billion ≈ $14.39 Million |
+5.40% |
| 2021-12-31 | ₩20.14 Billion ≈ $13.65 Million |
-13.70% |
| 2020-12-31 | ₩23.34 Billion ≈ $15.82 Million |
+10.58% |
| 2019-12-31 | ₩21.11 Billion ≈ $14.30 Million |
-11.95% |
| 2018-12-31 | ₩23.97 Billion ≈ $16.24 Million |
+24.17% |
| 2017-12-31 | ₩19.30 Billion ≈ $13.08 Million |
+33.23% |
| 2016-12-31 | ₩14.49 Billion ≈ $9.82 Million |
-35.84% |
| 2015-12-31 | ₩22.58 Billion ≈ $15.30 Million |
+55.88% |
| 2014-12-31 | ₩14.49 Billion ≈ $9.82 Million |
-6.44% |
| 2013-12-31 | ₩15.48 Billion ≈ $10.49 Million |
-16.66% |
| 2012-12-31 | ₩18.58 Billion ≈ $12.59 Million |
-16.50% |
| 2011-12-31 | ₩22.25 Billion ≈ $15.08 Million |
-- |
About Oscotec Inc
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody… Read more